by Five Rivers Rx | Oct 2, 2018 | Industry News, Regulations
Telehealth technology presents a unique opportunity to revolutionize multiple aspects of healthcare. 2018 has been a breakout year for telehealth – the majority of states now allow the practice of telepharmacy and healthcare practitioners are becoming more receptive...
by Five Rivers Rx | Sep 19, 2018 | Regulations
The DEA hosted a conference in San Antonio, TX that addressed multiple aspects of how those that manufacture, purchase, and/or sell controlled substances are regulated. Topic 1: Opioid Epidemic Will Glaspy – Special Agent in Charge of the Houston DEA office –...
by Five Rivers Rx | Aug 28, 2018 | Regulations
Key Reductions, 2019 versus 2018 per HDA: ANPP 88% Codeine (for conversion) 90% Dihydrocodeine 90% Dihydromorphine* 74% Fentanyl 88% Hydrocodone (for conversion) 4% Hydrocodone (for sale) 89% Hydromorphone 90% Meperidine 58% Morphine (for sale) 93% Opium (tincture)...
by Five Rivers Rx | Jul 24, 2018 | Regulations
In recent months, the DEA has begun ramping up its enforcement efforts across the pharmaceutical supply chain. In part one of this three-part series, we examine the “pharmacy” part of the supply chain with the Zion Clinic decision. Reasoning Behind the Zion Clinic...
by Five Rivers Rx | Jun 7, 2018 | Regulations
On June 7, 2018, the Engrossed Substitute House Bill 1047 (ESHB 1047) officially went into effect in the State of Washington for all holders of Washington State issued pharmaceutical licenses.¹ In an attempt to ensure “a ‘secure medicine take-back system for...
by Five Rivers Rx | Feb 27, 2018 | Regulations
DEA has “enhanced” its ARCOS online reporting system to help distributors and manufacturers know their customers better and detect suspicious orders. See here for more info. Using DEA’s new “ARCOS On-Line” tool, distributors and manufacturers can now enter the DEA...
